| pioglitazone vs glimepiride | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| all cause death, MI, stroke | 0.83 [0.25 2.75] | p=1.00 | 0 | 547 | 1 | PERISCOPE, | | cardiovascular events | 0.84 [0.37 1.92] | p=1.00 | 0 | 547 | 1 | PERISCOPE, | | Cardiovascular death | 2.99 [0.31 28.92] | p=1.00 | 0 | 547 | 1 | PERISCOPE, | | myocardial infarction (fatal and non fatal) | 0.50 [0.09 2.74] | p=1.00 | 0 | 547 | 1 | PERISCOPE, | | stroke (fatal and non fatal) | 0.33 [0.01 8.19] | p=1.00 | 0 | 547 | 1 | PERISCOPE, | | Heart failure | 0.80 [0.21 3.00] | p=1.00 | 0 | 547 | 1 | PERISCOPE, | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| pioglitazone vs metformin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.75 [0.17 3.37] | p=1.00 | 0 | 1194 | 1 | EC404, | | stroke (fatal and non fatal) | 0.50 [0.05 5.53] | p=1.00 | 0 | 1194 | 1 | EC404, | | Heart failure | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| pioglitazone vs placebo | No demonstrated result suggested all cause death, MI, stroke by 16% (not demonstrated) suggested Heart failure by 38% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| all cause death, MI, stroke | 0.84 [0.71 0.99] | p=0.04 | 0 | 6103 | 4 | PROactive,PNFP-026,PNFP-012,PNFP-001, | | cardiovascular events | 0.90 [0.80 1.02] | p=1.00 | 0 | 5238 | 1 | PROactive, | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.79 [0.60 1.04] | p=1.00 | 0 | 6103 | 4 | PROactive,PNFP-026,PNFP-012,PNFP-001, | | stroke (fatal and non fatal) | 0.81 [0.60 1.07] | p=1.00 | 0 | 6103 | 4 | PROactive,PNFP-026,PNFP-012,PNFP-001, | | Heart failure | 1.38 [1.07 1.77] | p=0.04 | 0 | 6103 | 4 | PROactive,PNFP-026,PNFP-012,PNFP-001, | | All cause death | 0.95 [0.77 1.17] | p=1.00 | 0 | 6103 | 4 | PROactive,PNFP-026,PNFP-012,PNFP-001, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| pioglitazone vs rosiglitazone | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| all cause death, MI, stroke | 0.40 [0.08 2.06] | p=1.00 | 0 | 735 | 1 | GLAI, | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.50 [0.04 5.49] | p=1.00 | 0 | 735 | 1 | GLAI, | | stroke (fatal and non fatal) | 0.33 [0.01 8.14] | p=1.00 | 0 | 735 | 1 | GLAI, | | Heart failure | 0.99 [0.02 50.12] | p=1.00 | 0 | 735 | 1 | GLAI, | | All cause death | 0.50 [0.04 5.49] | p=1.00 | 0 | 735 | 1 | GLAI, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| pioglitazone vs standard glucose-lowering drugs | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Heart failure | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| pioglitazone vs sulfonylurea | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| all cause death, MI, stroke | 0.95 [0.57 1.58] | p=1.00 | 0 | 2615 | 2 | OPI-504,OPI-506, | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.88 [0.45 1.70] | p=1.00 | 0 | 4667 | 5 | OPI-504,EC405,OPI-501,OPI-520,OPI-506, | | stroke (fatal and non fatal) | 1.31 [0.60 2.85] | p=1.00 | 0 | 4667 | 5 | OPI-504,EC405,OPI-501,OPI-520,OPI-506, | | Heart failure | 1.72 [0.97 3.03] | p=1.00 | 0 | 2615 | 2 | OPI-504,OPI-506, | | All cause death | 1.13 [0.49 2.57] | p=1.00 | 0 | 2615 | 2 | OPI-504,OPI-506, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| pioglitazone vs vildagliptin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Heart failure | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| pioglitazone + insulin vs placebo (add on insulin) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| all cause death, MI, stroke | 0.71 [0.07 6.86] | p=1.00 | 0 | 788 | 2 | PNFP-014,OPI-502, | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.71 [0.07 6.86] | p=1.00 | 0 | 788 | 2 | PNFP-014,OPI-502, | | stroke (fatal and non fatal) | 0.71 [0.04 11.38] | p=1.00 | 0 | 788 | 2 | PNFP-014,OPI-502, | | Heart failure | 2.22 [0.21 23.67] | p=1.00 | 0 | 788 | 2 | PNFP-014,OPI-502, | | All cause death | 0.71 [0.04 11.38] | p=1.00 | 0 | 788 | 2 | PNFP-014,OPI-502, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| pioglitazone + metformin vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| all cause death, MI, stroke | 0.95 [0.02 48.29] | p=1.00 | 0 | 328 | 1 | PNFP-027, | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.95 [0.02 48.29] | p=1.00 | 0 | 328 | 1 | PNFP-027, | | stroke (fatal and non fatal) | 0.95 [0.02 48.29] | p=1.00 | 0 | 328 | 1 | PNFP-027, | | Heart failure | 2.86 [0.12 70.66] | p=1.00 | 0 | 328 | 1 | PNFP-027, | | All cause death | 0.95 [0.02 48.29] | p=1.00 | 0 | 328 | 1 | PNFP-027, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| pioglitazone + metformin vs sulfonylurea + metformin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 4.94 [0.57 42.50] | p=1.00 | 0 | 630 | 1 | EC410, | | stroke (fatal and non fatal) | 0.66 [0.11 3.97] | p=1.00 | 0 | 630 | 1 | EC410, | | Heart failure | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| pioglitazone + sulfonylurea vs metformin + sulfonylurea | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.80 [0.21 3.02] | p=1.00 | 0 | 639 | 1 | EC409, | | stroke (fatal and non fatal) | 0.14 [0.02 1.17] | p=1.00 | 0 | 639 | 1 | EC409, | | Heart failure | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| pioglitazone + sulfonylurea vs sulfonylurea | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| all cause death, MI, stroke | 0.33 [0.06 2.02] | p=1.00 | 0 | 560 | 1 | PNFP-010, | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.50 [0.07 3.59] | p=1.00 | 0 | 560 | 1 | PNFP-010, | | stroke (fatal and non fatal) | 0.50 [0.01 25.37] | p=1.00 | 0 | 560 | 1 | PNFP-010, | | Heart failure | 0.10 [0.00 2.10] | p=1.00 | 0 | 560 | 1 | PNFP-010, | | All cause death | 0.25 [0.02 2.78] | p=1.00 | 0 | 560 | 1 | PNFP-010, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| rosiglitazone pioglitazone vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Heart failure | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
